What is the difference between Exenatide and Liraglutide?

Exenatide: First GLP-1 receptor agonist approved for clinical use (2005), derived from the Gila monster venom peptide exendin-4. Available as twice-daily immediate-release (Byetta) and once-weekly extended-release (Bydureon BCise) formulations. Established the GLP-1 agonist drug class and provided the foundational clinical evidence for cardiovascular and metabolic benefits. Liraglutide: Liraglutide is a once-daily GLP-1 receptor agonist — the first long-acting GLP-1 analog approved for both type 2 diabetes (Victoza, 1.8mg) and chronic weight management (Saxenda, 3mg). It was the foundational GLP-1 agonist that established the class's cardiovascular benefits and set the stage for semaglutide and tirzepatide. Both are in the GLP-1 & Metabolic category but differ in mechanism, dosing, and research evidence — see the full comparison.

Can you take Exenatide and Liraglutide together?

There is no specific, well-documented interaction rule for combining Exenatide and Liraglutide in the aggregated research reviewed. Combining peptides should only be considered under professional supervision. This is not medical advice.

Which is better researched, Exenatide or Liraglutide?

Exenatide is currently fda-approved and Liraglutide is fda-approved. "Better researched" depends on your research goal — review each profile's cited sources.

GLP-1 & Metabolic · Comparison

Exenatide vs Liraglutide

A neutral, side-by-side comparison of two glp-1 & metabolic peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

Exenatide

FDA-approved

First GLP-1 receptor agonist approved for clinical use (2005), derived from the Gila monster venom peptide exendin-4. Available as twice-daily immediate-release (Byetta) and once-weekly extended-release (Bydureon BCise) formulations. Established the GLP-1 agonist drug class and provided the foundational clinical evidence for cardiovascular and metabolic benefits.

Full profile

Liraglutide

FDA-approved

Liraglutide is a once-daily GLP-1 receptor agonist — the first long-acting GLP-1 analog approved for both type 2 diabetes (Victoza, 1.8mg) and chronic weight management (Saxenda, 3mg). It was the foundational GLP-1 agonist that established the class's cardiovascular benefits and set the stage for semaglutide and tirzepatide.

Full profile

	Exenatide	Liraglutide
Category	GLP-1 & Metabolic	GLP-1 & Metabolic
Also known as	Byetta, Bydureon, AC2993, exendin-4	NN2211, Victoza, Saxenda
Evidence	FDA-approved	FDA-approved
Dosing range	5mcg–2mg (weekly ER) mcg, Twice daily (immediate-release) or once weekly (extended-release)	0.6mg–3.0mg mg, Once daily subcutaneous injection
Administration	Subcutaneous injection	Subcutaneous injection (abdomen, thigh, or upper arm)
Key side effects	Nausea (most common, especially initial weeks), Vomiting, Diarrhea, Injection site nodules (extended-release formulation)	Nausea (most common, especially during initiation), Vomiting, Diarrhea, Decreased appetite
Cited sources	2 references	2 references

Key differences

Administration: Exenatide — Subcutaneous injection; Liraglutide — Subcutaneous injection (abdomen, thigh, or upper arm).
Dosing units differ: Exenatide is dosed in mcg, Liraglutide in mg — they operate at different scales.
Frequency: Exenatide is typically Twice daily (immediate-release) or once weekly (extended-release); Liraglutide is Once daily subcutaneous injection.

How each works

Exenatide

Exenatide was identified from Gila monster (Heloderma suspectum) venom as exendin-4, a peptide with ~53% homology to human GLP-1 but with DPP-4 resistance enabling longer activity. Clinical trials demonstrated HbA1c reductions of 0.8–1.0%, weight loss of 2–4kg, and cardiovascular safety (EXSCEL trial showed non-inferiority). The extended-release microsphere formulation achieved comparable efficacy with once-weekly dosing.

Liraglutide

The LEADER trial (N=9340) demonstrated significant reduction in major adverse cardiovascular events (MACE) in high-risk T2D patients — the first cardiovascular outcomes trial for a GLP-1 agonist. The SCALE trials showed 5–8% mean weight loss at 3mg/day vs placebo. While superseded by semaglutide and tirzepatide in weight loss efficacy, liraglutide has the longest safety record in the class (approved 2010) and daily dosing allows finer tolerability titration.

Read the full Exenatide profile Read the full Liraglutide profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.